Healthcare Triangle, Inc. 8-K

What Happened

• On June 12, 2026, Healthcare Triangle, Inc. announced completion of a private placement of 15% original-issue-discount (OID) senior convertible promissory notes with $4.235 million principal (gross proceeds ≈ $3.6 million before fees) and entered into an Equity Purchase Agreement with Hudson Global Ventures, LLC that commits up to $50 million of share purchases over a multi-year period. The Notes mature December 12, 2026; the Equity Purchase Agreement includes a related warrant and registration-rights arrangement. A press release announcing the closings was issued June 12, 2026.

Key Details

• Notes: $4.235 million aggregate principal, 15% OID, issued June 12, 2026; maturity December 12, 2026; convertible after six months at 85% of the 3‑day VWAP (floor $0.452/share); company may prepay at 102.5% of principal plus accrued interest.
• Equity Line: Up to $50,000,000 commitment from Hudson; commitment period ends on earliest of (i) full draw, (ii) 36 months, (iii) company termination or (iv) certain bankruptcy events.
• Pricing & limits: Each put under the equity line must be at least $25,000 and no more than the lesser of $2.5M and 200% of average daily trading value; purchase price equals the lesser of (i) 94% of the average of the three lowest traded prices during the prior five trading days and (ii) 94% of the lowest traded price during the valuation period.
• Warrant & registration: Hudson received a warrant for 50,000 shares at $0.00001/share (5‑year term). The company agreed to file a registration statement within 45 days and use best efforts to have it declared effective within 90 days; registration must remain effective until Hudson has sold its registrable securities and the equity commitment is fully drawn.
• Conditions and limits: Sales under the equity line are subject to conditions including effectiveness of the registration statement, Nasdaq shareholder-approval limitations, a 4.99% beneficial ownership cap, DWAC eligibility, and minimum pricing conditions. Failure to obtain required shareholder approval by December 12, 2026 would be an event of default under the Notes with liquidated damages per the agreements.

Why It Matters

• Provides near-term liquidity: The convertible note proceeds (≈$3.6M net before fees) and the $50M equity commitment (if accessed) give the company multiple ways to raise cash without a single large immediate equity issuance.
• Potential dilution and market impact: Conversions of the Notes and share sales under the equity line could dilute existing shareholders; pricing mechanics (discounts to recent trading prices and conversion at 85% VWAP) and the warrant issuance increase potential share supply.
• Conditional resale and approval risk: The Investor’s ability to sell relies on the company’s registration statement and Nasdaq/shareholder approvals; failure to secure required approvals by the notes’ maturity could trigger default and financial penalties.
• Investor takeaway: These arrangements materially affect the company’s capital structure and liquidity profile — important to monitor for dilution, timing of draws under the equity line, shareholder approval developments, and any subsequent financings.